NovaBay GAAP EPS of -1.27 misses by 0.71, revenue of 4.61M beats by 0.94M
| NBY Stock | USD 0.68 0.04 5.56% |
Slightly above 61% of NovaBay Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading NovaBay Pharmaceuticals stock suggests that many investors are alarmed at this time. NovaBay Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, NovaBay Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
NovaBay |
NovaBay press release Q2 GAAP EPS of -1.27 misses by 0.71.Revenue of 4.61M beats by 0.94M.
Read at seekingalpha.com
 |
NovaBay Pharmaceuticals Fundamental Analysis
We analyze NovaBay Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NovaBay Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NovaBay Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
NovaBay Pharmaceuticals is currently under evaluation in target price category among its peers.
NovaBay Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NovaBay Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of NovaBay Pharmaceuticals could also be used in its relative valuation, which is a method of valuing NovaBay Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
NovaBay Pharmaceuticals Related Equities
| IMMX | Immix Biopharma | 6.55 | ||||
| SONN | Sonnet Biotherapeutics | 3.11 | ||||
| PALI | Palisade Bio | 0.41 | ||||
| ZVSA | ZyVersa Therapeutics | 0.88 | ||||
| PHIO | Phio Pharmaceuticals | 2.37 | ||||
| ENVB | Enveric Biosciences | 2.94 | ||||
| CYTO | Altamira Therapeutics | 4.55 | ||||
| ZURA | Zura Bio | 6.83 | ||||
| CNSP | Cns Pharmaceuticals | 7.69 |
Additional Tools for NovaBay Stock Analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.